Werner Hacke

TL;DR: The DIAS-2 study did not show a benefit of desmoteplase given 3-9 h after the onset of stroke, and the high response rate in the placebo group could be explained by the mild strokes recorded (low baseline NIHSS scores, small core lesions, and small mismatch volumes that were associated with no vessel occlusions), which possibly reduced the potential to detect any effect.

TL;DR: Only parenchymal hematoma type 2 independently causes clinical deterioration and impairs prognosis, and has a distinct radiological feature: it is a dense homogeneous hematomas >30% of the ischemic lesion volume with significant space-occupying effect.

TL;DR: Early CT in acute middle cerebral artery trunk occlusion is highly predictive for fatal clinical outcome if there is extended hypodensity or local brain swelling despite aggressive therapeutic attempts such as thrombolysis or decompressive surgery.

TL;DR: Alteplase remains safe when given at 3-4.5 h after ischaemic stroke, offering an opportunity for patients who cannot be treated within the standard 3-h timeframe.

TL;DR: Stroke therapies have been aimed at the prevention of future cerebrovascular attacks, but no therapy is available to improve the outcome of patients with ischemic stroke.